<DOC>
	<DOC>NCT00788931</DOC>
	<brief_summary>The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer</brief_summary>
	<brief_title>A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; 18 year old Confirmed HER2+ metastatic breast cancer Prior treatment and progression on trastuzumab Patients must have adequate organ functions Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 1 Patients who have had surgery within last 2 weeks prior to starting the treatment Patients who receive concurrent therapy for brain metastases Impaired heart function or clinically significant heart disease Ongoing diarrhea Liver or renal disease with impaired hepatic or renal functions Concomitant use of any anticancer therapy or certain drugs Female patients who are pregnant or breast feeding Patients not willing to use an effective method of birth control Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>adult-female</keyword>
	<keyword>LBH589</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>panobinostat</keyword>
	<keyword>metastatic breast</keyword>
	<keyword>adult female patients</keyword>
</DOC>